Olivia Brayer
Stock Analyst at Cantor Fitzgerald
(3.74)
# 754
Out of 5,115 analysts
108
Total ratings
51.56%
Success rate
9.3%
Average return
Main Sectors:
Stocks Rated by Olivia Brayer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Maintains: Overweight | $216 → $230 | $156.87 | +46.62% | 1 | Dec 16, 2025 | |
| IKT Inhibikase Therapeutics | Initiates: Overweight | $4 | $1.50 | +166.67% | 1 | Dec 11, 2025 | |
| VNDA Vanda Pharmaceuticals | Maintains: Overweight | $13 → $11 | $7.54 | +45.89% | 2 | Oct 30, 2025 | |
| CTMX CytomX Therapeutics | Initiates: Overweight | $6 | $5.69 | +5.45% | 1 | Sep 22, 2025 | |
| GOSS Gossamer Bio | Reiterates: Overweight | n/a | $2.28 | - | 1 | Sep 11, 2025 | |
| UTHR United Therapeutics | Maintains: Overweight | $405 → $525 | $469.49 | +11.82% | 2 | Sep 10, 2025 | |
| BMRN BioMarin Pharmaceutical | Reiterates: Overweight | $90 | $56.54 | +59.18% | 15 | Feb 20, 2025 | |
| VRTX Vertex Pharmaceuticals | Reiterates: Overweight | $480 | $469.90 | +2.15% | 22 | Feb 11, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $50 → $55 | $55.05 | -0.09% | 9 | Feb 4, 2025 | |
| GILD Gilead Sciences | Reiterates: Neutral | $80 | $141.95 | -43.64% | 10 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $11.69 | - | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $1,015 | $741.45 | +36.89% | 8 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $405 | $341.88 | +18.46% | 2 | Oct 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $220 | $338.06 | -34.92% | 23 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $10 | $14.53 | -31.18% | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6.5 | $5.78 | +12.46% | 4 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $72 | $49.96 | +44.12% | 1 | Apr 13, 2023 |
Insmed
Dec 16, 2025
Maintains: Overweight
Price Target: $216 → $230
Current: $156.87
Upside: +46.62%
Inhibikase Therapeutics
Dec 11, 2025
Initiates: Overweight
Price Target: $4
Current: $1.50
Upside: +166.67%
Vanda Pharmaceuticals
Oct 30, 2025
Maintains: Overweight
Price Target: $13 → $11
Current: $7.54
Upside: +45.89%
CytomX Therapeutics
Sep 22, 2025
Initiates: Overweight
Price Target: $6
Current: $5.69
Upside: +5.45%
Gossamer Bio
Sep 11, 2025
Reiterates: Overweight
Price Target: n/a
Current: $2.28
Upside: -
United Therapeutics
Sep 10, 2025
Maintains: Overweight
Price Target: $405 → $525
Current: $469.49
Upside: +11.82%
BioMarin Pharmaceutical
Feb 20, 2025
Reiterates: Overweight
Price Target: $90
Current: $56.54
Upside: +59.18%
Vertex Pharmaceuticals
Feb 11, 2025
Reiterates: Overweight
Price Target: $480
Current: $469.90
Upside: +2.15%
Bristol-Myers Squibb Company
Feb 4, 2025
Maintains: Neutral
Price Target: $50 → $55
Current: $55.05
Upside: -0.09%
Gilead Sciences
Dec 11, 2024
Reiterates: Neutral
Price Target: $80
Current: $141.95
Upside: -43.64%
Nov 14, 2024
Reiterates: Neutral
Price Target: n/a
Current: $11.69
Upside: -
Oct 23, 2024
Reiterates: Neutral
Price Target: $1,015
Current: $741.45
Upside: +36.89%
Oct 22, 2024
Reiterates: Overweight
Price Target: $405
Current: $341.88
Upside: +18.46%
Oct 11, 2024
Reiterates: Neutral
Price Target: $220
Current: $338.06
Upside: -34.92%
Sep 16, 2024
Reiterates: Overweight
Price Target: $10
Current: $14.53
Upside: -31.18%
May 9, 2024
Reiterates: Overweight
Price Target: $6.5
Current: $5.78
Upside: +12.46%
Apr 13, 2023
Initiates: Overweight
Price Target: $72
Current: $49.96
Upside: +44.12%